Voronoi

Director of Medicinal Chemistry Laboratory

The company provides a reporting channel for employees to anonymously or openly disclose unethical conduct, unfair treatment, or violations of ethical business principles. It commits to protecting whistleblowers’ anonymity and confidentiality throughout investigations and ensures no retaliation or discrimination occurs in business or personnel matters.

Voronoi

Voronoi, Inc. cuts its clinical trial participant pool by 35% while pursuing extra funding despite the change. The company leverages credit spreads as a tool to gauge investor sentiment in corporate bond markets. Its platform, *Credit Signal*, delivers simplified trend analysis of market-wide conditions.

Oct 2026edailyNews article

Voronoi presents Phase 1 trial results for **VRN11**, its experimental EGFR-mutated NSCLC treatment. The biotech firm outlines a **U.S. FDA accelerated approval pathway** for the drug candidate. The company faces heightened scrutiny amid financial pressures in Korea’s biotech sector.

Sep 2026CHOSUNBIZNews article

VORONOI secures the KHIDI President’s Commendation for its open innovation work. The company completes five global technology transfer deals and sells technology assets as part of its innovation strategy. The recognition highlights its contributions to collaborative technology development.

Sep 2026Yahoo FinanceNews article

Voronoi, Inc. secures Investigational New Drug (IND) approval in Singapore for its lung cancer treatment **VRN11**, advancing its global Phase 1 clinical trials. The approval marks a key regulatory milestone for the biotech company’s pipeline, expanding access to testing in Asia. Voronoi’s treatment targets lung cancer with a novel mechanism, building on prior clinical progress.

Aug 2026edailyNews article